Literature DB >> 21689641

Endogenous activation of nAChRs and NMDA receptors contributes to the excitability of CA1 stratum radiatum interneurons in rat hippocampal slices: effects of kynurenic acid.

Manickavasagom Alkondon1, Edna F R Pereira, Edson X Albuquerque.   

Abstract

CA1 stratum radiatum interneurons (SRIs) express α7 nicotinic receptors (nAChRs) and receive inputs from glutamatergic neurons/axons that express α3β4β2 nAChRs. To test the hypothesis that endogenously active α7 and/or α3β4β2 nAChRs control the excitability of CA1 SRIs in the rat hippocampus, we examined the effects of selective receptor antagonists on spontaneous fast current transients (CTs) recorded from these interneurons under cell-attached configuration. The frequency of CTs, which represent action potentials, increased in the absence of extracellular Mg(2+) and decreased in the presence of the α3β4β2 nAChR antagonist mecamylamine (3 μM) or the NMDA receptor antagonist APV (50 μM). However, it was unaffected by the α7 nAChR antagonist MLA (10 nM) or the AMPA receptor antagonist CNQX (10 μM). Thus, in addition to synaptically and tonically activated NMDA receptors, α3β4β2 nAChRs that are present on glutamatergic axons/neurons synapsing onto SRIs and are activated by basal levels of acetylcholine contribute to the maintenance of the excitability of these interneurons. Kynurenic acid (KYNA), an astrocyte-derived kynurenine metabolite whose levels are increased in the brains of patients with schizophrenia, also controls the excitability of SRIs. At high micromolar concentrations, KYNA, acting primarily as an NMDA receptor antagonist, decreased the CT frequency recorded from the interneurons. At 2 μM, KYNA reduced the CA1 SRI excitability via mechanisms independent of NMDA receptor block. KYNA-induced reduction of excitability of SRIs may contribute to sensory gating deficits that have been attributed to deficient hippocampal GABAergic transmission and high levels of KYNA in the brain of patients with schizophrenia.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689641      PMCID: PMC5673494          DOI: 10.1016/j.bcp.2011.06.004

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  32 in total

1.  Contributions of intrinsic and synaptic activities to the generation of neuronal discharges in in vitro hippocampus.

Authors:  I Cohen; R Miles
Journal:  J Physiol       Date:  2000-04-15       Impact factor: 5.182

2.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

3.  Functional nicotinic ACh receptors on interneurones in the rat hippocampus.

Authors:  S Jones; J L Yakel
Journal:  J Physiol       Date:  1997-11-01       Impact factor: 5.182

4.  Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory.

Authors:  E D Levin; A Bradley; N Addy; N Sigurani
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

5.  Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry.

Authors:  A Konradsson-Geuken; H Q Wu; C R Gash; K S Alexander; A Campbell; Y Sozeri; R Pellicciari; R Schwarcz; J P Bruno
Journal:  Neuroscience       Date:  2010-06-19       Impact factor: 3.590

6.  Nicotinic receptor subtypes in rat hippocampal slices are differentially sensitive to desensitization and early in vivo functional up-regulation by nicotine and to block by bupropion.

Authors:  Manickavasagom Alkondon; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2005-01-12       Impact factor: 4.030

7.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

8.  Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats.

Authors:  Trevor W Stone
Journal:  Eur J Neurosci       Date:  2007-04-25       Impact factor: 3.386

Review 9.  Studies on the hippocampal formation: From basic development to clinical applications: Studies on schizophrenia.

Authors:  Robert Freedman; Dan Goldowitz
Journal:  Prog Neurobiol       Date:  2009-10-21       Impact factor: 11.685

Review 10.  Mammalian nicotinic acetylcholine receptors: from structure to function.

Authors:  Edson X Albuquerque; Edna F R Pereira; Manickavasagom Alkondon; Scott W Rogers
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

View more
  12 in total

Review 1.  Regulation of hippocampal inhibitory circuits by nicotinic acetylcholine receptors.

Authors:  Marilena Griguoli; Enrico Cherubini
Journal:  J Physiol       Date:  2011-11-28       Impact factor: 5.182

Review 2.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

3.  Regulation of GABAergic inputs to CA1 pyramidal neurons by nicotinic receptors and kynurenic acid.

Authors:  Jyotirmoy Banerjee; Manickavasagom Alkondon; Edna F R Pereira; Edson X Albuquerque
Journal:  J Pharmacol Exp Ther       Date:  2012-02-17       Impact factor: 4.030

4.  Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Authors:  Ikwunga Wonodi; Robert P McMahon; Nithin Krishna; Braxton D Mitchell; Judy Liu; Matthew Glassman; L Elliot Hong; James M Gold
Journal:  Schizophr Res       Date:  2014-11-14       Impact factor: 4.939

Review 5.  Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.

Authors:  Michael Y Bai; David B Lovejoy; Gilles J Guillemin; Rouba Kozak; Trevor W Stone; Maju Mathew Koola
Journal:  Complex Psychiatry       Date:  2021-02-08

Review 6.  The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.

Authors:  Trevor W Stone; L Gail Darlington
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

7.  Acetylcholinesterase inhibition reveals endogenous nicotinic modulation of glutamate inputs to CA1 stratum radiatum interneurons in hippocampal slices.

Authors:  Manickavasagom Alkondon; Edson X Albuquerque; Edna F R Pereira
Journal:  Neurotoxicology       Date:  2013-03-16       Impact factor: 4.294

8.  Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice.

Authors:  Dániel Varga; Judit Herédi; Zita Kánvási; Marian Ruszka; Zsolt Kis; Etsuro Ono; Naoki Iwamori; Tokuko Iwamori; Hiroki Takakuwa; László Vécsei; József Toldi; Levente Gellért
Journal:  Front Behav Neurosci       Date:  2015-06-16       Impact factor: 3.558

9.  Lack of modulation of nicotinic acetylcholine alpha-7 receptor currents by kynurenic acid in adult hippocampal interneurons.

Authors:  Peter Dobelis; Kevin J Staley; Donald C Cooper
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

10.  Altered hippocampal plasticity by prenatal kynurenine administration, kynurenine-3-monoxygenase (KMO) deletion or galantamine.

Authors:  C M Forrest; K McNair; M Pisar; O S Khalil; L G Darlington; T W Stone
Journal:  Neuroscience       Date:  2015-09-10       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.